Coverage and coding

Use the specific ICD-10-CM codes below when filing claims to indicate a moderate to severe dyspareunia due to menopause:
  • N94.10 Unspecified dyspareunia
  • N94.11 Superficial (introital) dyspareunia
  • N94.12 Deep dyspareunia
  • N94.19 Other specified dyspareunia
Rx Prescription image
See More


INTRAROSA is a steroid indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.

Important Safety Information

INTRAROSA is contraindicated in women with undiagnosed abnormal genital bleeding.

Estrogen is a metabolite of prasterone. Use of exogenous estrogen is contraindicated in women with a known or suspected history of breast cancer. INTRAROSA has not been studied in women with a history of breast cancer.

In four 12-week randomized, placebo-controlled clinical trials, the most common adverse reaction with an incidence ≥2 percent was vaginal discharge. In one 52-week open-label clinical trial, the most common adverse reactions with an incidence ≥2 percent were vaginal discharge and abnormal Pap smear.

To report SUSPECTED ADVERSE REACTIONS, contact AMAG Pharmaceuticals at 1­-877-411-2510 or FDA at 1-800­-FDA-1088 or

Please see full Prescribing Information.

References: 1. Data on file. AMAG Pharmaceuticals, Inc., Waltham, MA 02451. 2. Dyspareunia. website.
Codes/N00-N99/N80-N98/N94-/N94.1. Updated January 5, 2018. Accessed March 13, 2018.